Logo image of ARMP

ARMATA PHARMACEUTICALS INC (ARMP) Stock Fundamental Analysis

USA - NYSEARCA:ARMP - US04216R1023 - Common Stock

6.06 USD
-1.04 (-14.65%)
Last: 10/24/2025, 8:09:25 PM
5.87 USD
-0.19 (-3.14%)
Pre-Market: 10/27/2025, 5:02:44 AM
Fundamental Rating

2

ARMP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative. ARMP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARMP had negative earnings in the past year.
In the past year ARMP has reported a negative cash flow from operations.
ARMP had negative earnings in each of the past 5 years.
ARMP had a negative operating cash flow in each of the past 5 years.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.82%, ARMP is in the better half of the industry, outperforming 65.54% of the companies in the same industry.
Industry RankSector Rank
ROA -31.82%
ROE N/A
ROIC N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARMP has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ARMP has been increased compared to 5 years ago.
Compared to 1 year ago, ARMP has a worse debt to assets ratio.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.23, we must say that ARMP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.23, ARMP is not doing good in the industry: 70.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.23
ROIC/WACCN/A
WACC8.03%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

ARMP has a Current Ratio of 0.06. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
ARMP has a Current ratio of 0.06. This is amonst the worse of the industry: ARMP underperforms 97.57% of its industry peers.
ARMP has a Quick Ratio of 0.06. This is a bad value and indicates that ARMP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ARMP (0.06) is worse than 97.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

ARMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.05%, which is quite impressive.
The Revenue has grown by 84.43% in the past year. This is a very strong growth!
ARMP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.00% yearly.
EPS 1Y (TTM)58.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)84.43%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ARMP will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.20% on average per year.
Based on estimates for the next years, ARMP will show a very strong growth in Revenue. The Revenue will grow by 78.86% on average per year.
EPS Next Y-186.38%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2027 2028 10M 20M 30M 40M 50M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 200 -200 400 600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.83%
EPS Next 3Y4.37%

More info and screens

0

5. Dividend

5.1 Amount

ARMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (10/24/2025, 8:09:25 PM)

Premarket: 5.87 -0.19 (-3.14%)

6.06

-1.04 (-14.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners2.03%
Inst Owner Change-0.14%
Ins Owners0.07%
Ins Owner Change-0.13%
Market Cap219.55M
Revenue(TTM)6.87M
Net Income(TTM)-25707000
Analysts82.86
Price Target9.18 (51.49%)
Short Float %0.22%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.64%
Min EPS beat(2)-13.12%
Max EPS beat(2)48.4%
EPS beat(4)3
Avg EPS beat(4)50.59%
Min EPS beat(4)-13.12%
Max EPS beat(4)119.61%
EPS beat(8)4
Avg EPS beat(8)6.07%
EPS beat(12)6
Avg EPS beat(12)9.4%
EPS beat(16)8
Avg EPS beat(16)6.16%
Revenue beat(2)1
Avg Revenue beat(2)-5.54%
Min Revenue beat(2)-65.13%
Max Revenue beat(2)54.05%
Revenue beat(4)2
Avg Revenue beat(4)47.6%
Min Revenue beat(4)-65.13%
Max Revenue beat(4)223.86%
Revenue beat(8)4
Avg Revenue beat(8)22.06%
Revenue beat(12)4
Avg Revenue beat(12)1.27%
Revenue beat(16)7
Avg Revenue beat(16)7.11%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16%
EPS NY rev (1m)0%
EPS NY rev (3m)24.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.97
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.19
BVpS-1.92
TBVpS-2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.53%
ROA(5y)-43.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.59%
Cap/Sales 7.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -8.23
F-Score4
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)409.33%
Cap/Depr(5y)282.59%
Cap/Sales(3y)85.41%
Cap/Sales(5y)77.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
EPS Next Y-186.38%
EPS Next 2Y-26.83%
EPS Next 3Y4.37%
EPS Next 5Y16.2%
Revenue 1Y (TTM)84.43%
Revenue growth 3Y5%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.46%
Revenue Next 5Y78.86%
EBIT growth 1Y16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A

ARMATA PHARMACEUTICALS INC / ARMP FAQ

What is the ChartMill fundamental rating of ARMATA PHARMACEUTICALS INC (ARMP) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARMP.


What is the valuation status of ARMATA PHARMACEUTICALS INC (ARMP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARMATA PHARMACEUTICALS INC (ARMP). This can be considered as Overvalued.


How profitable is ARMATA PHARMACEUTICALS INC (ARMP) stock?

ARMATA PHARMACEUTICALS INC (ARMP) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARMATA PHARMACEUTICALS INC (ARMP) stock?

The Earnings per Share (EPS) of ARMATA PHARMACEUTICALS INC (ARMP) is expected to decline by -186.38% in the next year.